Living With Fatty Liver, MASH, Fibrosis or Cirrhosis?
Here’s What to Know
Being told that you have fatty liver disease, MASH, liver fibrosis, or cirrhosis can bring a lot of questions.
You may wonder how serious your condition is, whether it can get worse, what your test results mean, and what options may be available to you.
For some people, liver disease causes noticeable symptoms such as fatigue, weakness, abdominal discomfort, or swelling. For others, it may progress quietly with few or no symptoms at all. In fact, liver disease can sometimes remain unnoticed until significant liver damage has already developed.
The important thing to know is that liver disease exists on a spectrum, and learning more about your liver health can help you have better conversations with your healthcare provider
Clinical Trial Network (CTN) in Houston is currently conducting clinical research involving people at different stages of liver disease, including fatty liver disease, MASH/NASH, liver fibrosis and cirrhosis. Depending on the specific study and eligibility requirements, qualified participants may also receive study-related liver evaluations at no cost.
This article explains MASH, liver scarring and cirrhosis in plain language, while also introducing a Houston clinical research opportunity available through CTN.
What Is MASH?
MASH stands for Metabolic Dysfunction-Associated Steatohepatitis.
It is a form of metabolic liver disease in which excess fat accumulates in the liver and is associated with inflammation and liver-cell injury. Over time, ongoing liver injury can contribute to the development of scar tissue, known as fibrosis.
You may have heard the older terms NASH or NAFLD.
In 2023, international liver organizations introduced updated terminology. Nonalcoholic Fatty Liver Disease, or NAFLD, is now commonly referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease, or MASLD. NASH was renamed Metabolic Dysfunction-Associated Steatohepatitis, or MASH.
The terminology changed, but people who were previously diagnosed with NASH may now hear their condition described as MASH.
How Can Fatty Liver Disease Progress?
Liver disease does not usually progress from a healthy liver to cirrhosis overnight.
Instead, changes may happen gradually.
A person may begin with fat accumulation in the liver. In some people, inflammation and liver-cell damage develop. Continued injury can then lead to fibrosis, which means scar tissue is forming within the liver.
When scarring becomes extensive and permanently changes the structure of the liver, the condition is known as cirrhosis.
Cirrhosis can interfere with the liver's ability to perform important functions. The National Institute of Diabetes and Digestive and Kidney Diseases describes cirrhosis as a condition in which scar tissue replaces healthy liver tissue and prevents the liver from working normally.
This is also why CTN's current liver research includes people with different forms and stages of liver disease rather than focusing only on people with advanced cirrhosis. CTN notes that studying participants from fatty liver through advanced liver scarring can help researchers better understand disease progression and potential future treatment approaches.
Liver Disease Can Be Difficult to Notice
One of the challenges with metabolic liver disease is that symptoms do not always match the amount of liver damage.
Some people may have little or no noticeable symptoms during earlier stages. Even people who have developed cirrhosis related to MASH may sometimes have relatively few symptoms.
When symptoms are present, they can include tiredness, weakness, reduced appetite, discomfort in the upper-right abdomen, unexplained weight changes, or swelling in the legs or abdomen. Symptoms can become more noticeable as liver function worsens.
Because symptoms alone cannot tell you what stage of liver disease you have, medical evaluation and appropriate liver testing can be important.
What Is Compensated Cirrhosis?
Cirrhosis means that significant liver scarring has developed.
However, not everyone with cirrhosis experiences severe liver failure.
In compensated cirrhosis, significant scar tissue is present, but the liver is still able to perform many of its essential functions. A person may continue carrying out normal daily activities and may not realize how much their liver disease has progressed.
CTN is currently conducting clinical research specifically involving adults with compensated cirrhosis related to MASH/NASH.
Why Clinical Research Matters for Liver Disease
Clinical research helps physicians and researchers learn more about how liver disease develops and evaluate potential new approaches to treatment.
Before new treatments become broadly available, researchers need carefully controlled studies to understand their safety, effectiveness, and appropriate use.
Participation in a clinical study is always voluntary.
Before joining, potential participants go through an informed-consent process in which the research team explains the study, study procedures, potential risks, possible benefits, visit requirements and other important details.
You can ask questions before deciding whether participation is right for you.
Clinical Trial Network is currently recruiting for liver-related clinical research in Houston, Texas.
CTN's current research includes people with fatty liver disease, MASH/NASH, liver fibrosis or scarring, and cirrhosis. One of CTN's studies specifically evaluates an investigational approach for adults living with compensated cirrhosis caused by MASH.
CTN has also indicated that its liver research efforts are designed to evaluate people across different stages of liver disease. Final eligibility depends on the requirements of the particular study protocol and medical screening.
Qualified participants may receive:
-
Study-related liver blood work at no cost, valued at approximately $300
-
A study-related liver scan at no cost, valued at approximately $500
-
$75 compensation for each completed study visit
-
Study-related medical evaluations and liver-health assessments
-
Monitoring by experienced clinical research professionals
-
The opportunity to contribute to research that may help improve future approaches to liver disease
The complimentary liver blood work and liver scan are available upon qualification, and completing an initial form or screening does not guarantee enrollment.
CTN's published study information also notes that qualifying liver-study procedures may include blood and urine testing, liver assessments, FibroScan® evaluations, imaging, physical examinations and regular follow-up visits, depending on the study protocol.
Benefits Available to Qualified Participants
Who Should Consider Reaching Out?
You do not necessarily have to wait until you have advanced cirrhosis to ask CTN whether a liver study may be suitable for you.
It may be worth completing an eligibility screening if you have previously been told that you have fatty liver disease, MASLD, MASH or NASH, liver fibrosis, liver scarring, elevated liver enzymes, or cirrhosis.
CTN's current MASH/cirrhosis study lists adults ages 18 to 80 with compensated cirrhosis related to MASH/NASH among the people who may qualify. CTN's broader liver-cirrhosis research also considers people with fatty liver disease and different stages of liver damage. Exact requirements vary from one study to another.
The research team makes the final eligibility determination after reviewing medical history, laboratory findings, and other study-specific criteria.
What Does “Investigational Treatment” Mean?
An investigational treatment is a treatment that researchers are still studying for a particular condition or patient population.
Clinical trials are conducted because researchers need additional evidence about safety, effectiveness, dosing, long-term outcomes, or how a treatment compares with other approaches.
It is therefore important not to think of an investigational treatment as a guaranteed treatment or guaranteed benefit.
CTN's current MASH compensated-cirrhosis study is randomized and placebo-controlled. That means qualifying participants are randomly assigned to a study group, and some may receive a placebo rather than the investigational treatment.
The research team will explain these details during the informed-consent process before you decide whether to participate.
What Happens After You Contact CTN?
Taking the first step does not mean that you are agreeing to join a clinical trial.
Usually, the process begins with an eligibility form or a conversation with the research team. You may be asked some preliminary questions about your age, medical history, previous liver diagnoses, medications and other health information.
If the initial information suggests that you could potentially qualify, the research team may schedule additional screening.
Study-specific medical testing may then be performed to determine whether all eligibility requirements are met.
If you qualify, CTN will explain what participation involves before you make your final decision.
Participation remains voluntary.
Is a Liver Clinical Study Right for You?
There is no single answer that applies to everyone.
Some people explore clinical research because they want to learn more about their liver health, have access to structured study-related monitoring, or contribute to research that may help future patients.
Others may prefer to continue exclusively with their existing healthcare plan.
You should never feel pressured to participate.
You can contact the research team simply to learn more, ask questions, and find out whether a study might apply to your situation.
Clinical research should also not replace regular medical care. Continue working with your physician or liver specialist regarding diagnosis, treatment, and medical decisions.
Take the Next Step With CTN
Whether you have recently been told you have fatty liver disease or have already been diagnosed with MASH, fibrosis or cirrhosis, understanding your liver health is an important step.
Clinical Trial Network in Houston is currently evaluating potential participants for liver-related clinical research.
Qualified participants may receive liver blood work valued at approximately $300, a liver scan valued at approximately $500, and $75 for each completed study visit, subject to study eligibility and participation requirements.
Participation is voluntary, and submitting an eligibility form does not guarantee enrollment. Final eligibility is determined by the clinical research team.